Brazil accuses Lilly of delaying generics; Amazon meets with FDA, but why?;

@FiercePharma: Top-read news in FP Thurs: Pfizer eyes Actavis in backup plan to another AstraZeneca bid. Article | Follow @FiercePharma

@TracyStaton: ICYMI this week: CEO on the house that Victoza built and the future of diabetes R&D. Report | Follow @TracyStaton

@EricPFierce: DEA tightens prescribing, limits refills on opioid combo pills like #Vicodin. Story | Follow @EricPFierce

@CarlyHFierce: ICYMI earlier - Report: Takeda's dengue jab will be nipping at Sanofi's heels by 2020. Article | Follow @CarlyHFierce

> Eli Lilly ($LLY) has been accused in Brazil of filing unnecessary lititgation to try to hold off generic competition to a drug. Report

> The European Medicines Agency has agreed to review Cubist Pharmaceuticals' ($CBST) investigational antibiotic ceftolozane/tazobactam for urinary tract and abdominal infections. Release

> Mylan ($MYL) has launched a generic version of Upsher-Smith's Klor-Con for low potassium. Release

> A study from the Canadian Health Policy Institute says that the longer time that Canada takes to approve drugs, compared to the EU, has not resulted in a fewer risks for residents. Report

Medical Device News

@FierceMedDev: Claret Medical ropes in $18M to develop cerebral protection system for TAVR procedures. ICYMI yesterday | Follow @FierceMedDev

@VarunSaxena2: UPDATED with table of deadlines: FDA clarifies UDI requirements with new guidance. Story | Follow @VarunSaxena2

@EmilyWFierce: Pruning of synapses in brain could provide clues to how autism develops in children, say scientists. More from the NYT | Follow @EmilyWFierce

> Google Ventures, Kleiner Perkins back enterprise wearables startup. More

> FDA clears AliveCor smartphone plug-in heart monitor to detect atrial fibrillation. Article

> Claret Medical ropes in $18M to develop cerebral protection system for TAVR procedures. Story

Biotech News

@FierceBiotech: Low levels of enzyme in Alzheimer's brains suggest new drug target. More from FierceBiotech Research | Follow @FierceBiotech

@JohnCFierce: ICYMI yesterday: J&J, AstraZeneca and Sanofi join Illumina to create a pan-cancer test. Report | Follow @JohnCFierce

@DamianFierce: A glimpse at the glamorous hedonism that runs rampant in Big Pharma. Image | Follow @DamianFierce

@EmilyMFierce: Parents more likely to vaccinate kids against measles when child's, not society's, benefits are stressed. FierceVaccines story | Follow @EmilyMFierce

> Pfizer-AstraZeneca sequel could hit theaters next week. Article

> Cubist nears another big antibiotic approval as M&A rumors simmer. Story

> Israel's NeuroDerm banks $16M to advance its Parkinson's pump. More

And Finally... Speculation about why Amazon ($AMZN) officials met with the FDA ranges from the retailer wanting to sell FDA regulated products online to doing something itself in the mobile healthcare arena. Story

Suggested Articles

Horizon Therapeutics has notched an FDA approval for its rare eye disease med Tepezza (teprotumumab), a possible blockbuster drug in the making.

Eli Lilly has a pipeline stuffed with a host of assets and has decided it needs a new injectable drug and device plant to manufacture some of them.

After Clovis’ Rubraca snagged an FDA boost in prostate cancer last week, AZ and Merck’s rival Lynparza has matched it with a boost of its own.